Furthermore, SF3B1 and U2AF1 mutant, but not SRSF2 mutant AML cells from the BEAT AML ex vivo drug screening showed preferential sensitivity to XPO1 inhibition. Here, SRSF2 is linked to acute myeloid leukemia.